Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy? ; day:4 ; month:6 ; year:2024 ; pages:1-14
British journal of cancer ; (4.6.2024), 1-14
- Creator
-
Karaboué, Abdoulaye
Innominato, Pasquale F.
Wreglesworth, Nicholas I.
Duchemann, Boris
Adam, René
Lévi, Francis A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-024-02704-9
- URN
-
urn:nbn:de:101:1-2408112116527.323629629125
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Karaboué, Abdoulaye
- Innominato, Pasquale F.
- Wreglesworth, Nicholas I.
- Duchemann, Boris
- Adam, René
- Lévi, Francis A.
- SpringerLink (Online service)
Other Objects (12)
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
Circadian rhythms and cancer: implications for timing in therapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint analysis in lip cancer
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitor-related acral vasculitis
Immune Checkpoint Blockers and Ovarian Cancer
Immune checkpoint blockade in ovarian cancer
Immune checkpoint analysis in ear cancer
Immune checkpoint therapy in liver cancer
Smoldering myocarditis following immune checkpoint blockade
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
Circadian rhythms and cancer: implications for timing in therapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint analysis in lip cancer
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitor-related acral vasculitis
Immune Checkpoint Blockers and Ovarian Cancer
Immune checkpoint blockade in ovarian cancer
Immune checkpoint analysis in ear cancer
Immune checkpoint therapy in liver cancer
Smoldering myocarditis following immune checkpoint blockade
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
Circadian rhythms and cancer: implications for timing in therapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint analysis in lip cancer
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitor-related acral vasculitis
Immune Checkpoint Blockers and Ovarian Cancer
Immune checkpoint blockade in ovarian cancer
Immune checkpoint analysis in ear cancer
Immune checkpoint therapy in liver cancer